Production ramped up to aid treatment, vaccine development

MilliporeSigma is in the process of adding 160 jobs at its Jaffrey facility as the global life sciences company ramps up production of components used to develop potential Covid-19 treatments and vaccines.

The company began hiring in Jaffrey in June and will continue through the end of the year, said David Poggi, the plant’s director of operations. So far, MilliporeSigma has added about 80 new employees.

The job openings range from entry-level manufacturing positions to engineering, technician and leadership roles. By the end of the hiring push, the Jaffrey facility will employ more than 1,200 people and will operate 24/7, Poggi added. All of the roles the company is looking to fill are important, Poggi said, but MilliporeSigma is especially focused on adding manufacturing jobs.

For the job openings, MilliporeSigma will consider candidates with a wide range of experience, including restaurant, retail and/or previous manufacturing experience.

“First and foremost what we’re looking for is a strong work ethic, strong work history and the curiosity and ambition to grow with us,” Poggi said.

Surge in demand

The hiring process started slowly in June, Poggi said, when the federal government was subsidizing unemployment insurance as part of its coronavirus relief efforts, but has since accelerated.

“So, in many cases, it appeared that a lot of the folks that were unemployed were actually opting to stay home and wait things out on unemployment,” Poggi said. “We’ve seen a change in that over the course of the last month, if you will, where we see more and more people reentering the job market, which is good to see.”

He added that he’s “hopeful that we’re going to be able to ramp up as planned. I wasn’t that hopeful a couple of months ago, when we were seeing a lot of folks kind of staying out of the hiring pool.”

The new round of hiring is necessary because MilliporeSigma has experienced a surge in demand for its products since the beginning of the Covid-19 pandemic.

“Prior to the pandemic, we had a very high growth rate to begin with,” Poggi said. “As we entered the year, and the pandemic hit, our growth rate was compounded because of all of the efforts right now to develop and produce Covid-related treatments and therapies, which our products are used in the standard template for vaccine manufacturing.”

MilliporeSigma’s Jaffrey facility primarily makes filtration devices that are used to produce biopharmaceuticals, such as immunotherapies for cancer treatment. These sorts of products are also part of the standard process for making vaccines, Poggi said. The company’s customers are mainly pharmaceutical corporations, and MiliporeSigma is currently supplying more than 45 companies that are working to develop a Covid-19 vaccine, spokeswoman Karen Tiano said.

Facility addition

MilliporeSigma is part of the German company Merck KGaA and has U.S. corporate offices in Burlington, Mass., and St. Louis, Mo.

The company employs more than 22,000 people worldwide. MiliporeSigma’s Jaffrey facility at 11 Prescott Road opened in 1972.

The hiring ramp-up comes as the Jaffrey facility is physically expanding, too. The company is adding additional lab and manufacturing space, including a 24,200-squarefoot, single-story addition and a separate 11,600-square-foot, two-story building. The Jaffrey Planning Board approved plans for the expansion in June 2019, and the project should be complete within the next 18 months, Poggi said.

The addition of more space and more employees go hand-in-hand, he added.

“They’re all part of our growth strategy to supply the products required to support the effort for Covid vaccine and therapies,” Poggi said.

This article is being shared by partners in The Granite State News Collaborative. For more information, visit collaborativenh.org.